NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces that it has commenced an investigation of TG Therapeutics, Inc. (NASDAQCM:TGTX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

TG Therapeutics, Inc. filed a press release on October 13, 2016 announcing that the Company had filed with the FDA an amended protocol for its leukemia drug combination, GENUINE Phase 3 Trial. In the amendments, the Company eliminated part II of the GENUINE study and reduced the number of randomized patients from 200 to approximately 120. The Company no longer benefits from of its previously negotiated Special Protocol Assessment with the FDA. Following this news, TG Therapeutics, Inc. stock dropped approximately 17% (-$1.42) to $6.83 per share on intraday trading.

To obtain additional information about the investigation, go to:

http://zlk.9nl.com/TG_Therapeutics_TGTX

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161014005376/en/